Treating gliomas with glucocorticoids: from bedside to bench

Area of Science:

• Neuro-oncology
• Pharmacology
• Cancer Biology

Background:

• Glucocorticoids are standard supportive care for glioma patients, primarily for managing tumor-associated edema and radiotherapy-induced encephalopathy.
• The precise molecular mechanisms underlying glucocorticoid efficacy in glioma treatment remain incompletely understood.

Purpose of the Study:

• To comprehensively review the experimental and clinical evidence on glucocorticoid effects in glioma.
• To elucidate the impact of glucocorticoids on key cancer hallmarks including proliferation, apoptosis, chemotherapy sensitivity, angiogenesis, and vascular permeability.
• To summarize current clinical guidelines for glucocorticoid therapy in glioma management.

Main Methods:

• Systematic review of preclinical (experimental) and clinical studies.
• Analysis of data pertaining to glucocorticoid actions on tumor cell biology and tumor microenvironment.
• Evaluation of existing treatment guidelines for glioma patients.

Main Results:

• Glucocorticoids influence glioma cell proliferation, apoptosis, and chemosensitivity.
• Evidence suggests glucocorticoids affect angiogenesis and vascular permeability within the tumor microenvironment.
• Current guidelines provide recommendations on glucocorticoid selection, dosage, and treatment duration.

Conclusions:

• Understanding glucocorticoid mechanisms is crucial for optimizing glioma treatment.
• Further research is needed to fully elucidate these pathways and refine therapeutic strategies.
• Evidence-based guidelines aid in the appropriate clinical application of glucocorticoids for glioma.